Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Ipilimumab
Related studies linked through entity extraction aliases.
Cryoablation+Ipilimumab+Nivolumab in Melanoma
- Status
- RECRUITING
- Phase
- PHASE2
Immunotherapy in Patients With Early dMMR Rectal Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
- Status
- RECRUITING
- Phase
- PHASE2
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE2
A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant
- Status
- WITHDRAWN
- Phase
- PHASE1
Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- Status
- RECRUITING
- Phase
- PHASE2